Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core Viewpoint - Investors in Jasper Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of alleged misrepresentations by the company regarding its manufacturing controls and product prospects [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that from November 30, 2023, to July 3, 2025, Jasper Therapeutics failed to disclose critical information, including the lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - This failure is claimed to have increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, particularly briquilimab [3]. - The lawsuit also suggests that the company's business and financial prospects were overstated, and that positive statements made by the defendants were materially misleading [3]. Participation Information - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before November 18, 2025, to participate in the ongoing class action lawsuit [2][4]. - Individuals do not need to take any immediate action to be part of the class action and may choose to retain counsel or remain absent [5].